Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2

BACKGROUND: Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-ly...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pediatr Blood Cancer
Päätekijät: Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Lu, Xiaomin, Devidas, Meenakshi, Reid, Joel M., Goldenberg, David M., Wegener, William A., Zeng, Hui, Whitlock, James A., Adamson, Peter C., Hunger, Stephen P., Carroll, William L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701208/
https://ncbi.nlm.nih.gov/pubmed/25732247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25454
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia